Global Opioid Induced Side Effects Treatment Market Is Anticipated To Witness High Growth Owing To Growing Availability Of Advanced Healthcare Infrastructure And Increasing Product Approval

Opioid Induced Side Effects Treatment Market

Overview:

There are a number of ways to help manage the side effects of opioids. These consist of symptomatic management, changing the route of administration, opioid rotation, and dose reduction. The most common side effects of opioids are nausea and constipation. Nausea occurs in approximately 25% of patients receiving opioids and is induced by several mechanisms, including gastric upset and the activation of the chemoreceptor trigger zone (CTZ), and vestibular sensitivity. Nausea is a serious problem that can lead to emetic behaviors and may require anti-emetic medication and prophylactic measures. Other common side effects of opioids are sedation and delirium. These effects are usually well controlled by dose reduction, symptomatic management, or opioid rotation. Dose reduction of up to 25% is a good first step in managing side effects. This approach should be performed in conjunction with the use of an equianalgesic table to calculate the appropriate lowered dose for each patient.

Market Dynamics:

Rising product launches are estimated to augment the growth of the global opioid induced side effects treatment market over the forecast period. For instance, an authorized generic of Narcan Nasal Spray was launched by Sandoz in December 2021, in the United States. This will help in treating people suffering from overdosing on opioids. Moreover, growing side effects related to drug addiction are anticipated to restrain the growth of the global opioid-induced side effects treatment market over the forecast period.

Impact of COVID-19:

COVID-19 was first recognized in 2019 in China. This outbreak resulted in shutting down the entire nation. Later on, it was transmitted to more than 100 nations. During the pandemic, strict restrictions like social distancing and quarantines were imposed to prevent the spread of the virus. These led to an increase in the number of opioid overdose deaths, owing to isolation, loss of mental health support, and increased stress. During the pandemic, many treatments were delayed or canceled, which also hampered the opioid-induced side effects treatment. This had a negative impact on the growth of the global opioid-induced side effects treatment market during the pandemic.

Key Takeaways:

The global opioid-induced side effects treatment market is expected to witness high growth, exhibiting a CAGR of 4.5 % over the forecast period, due to increasing acquisitions by key players. For instance, a branded opioid product Onsolis was acquired by Adalvo in August 2022. Opioid is used for managing chronic pain in cancer.

North America is anticipated to witness significant growth in the global opioid-induced side effects treatment market over the forecast period, owing to the growing prevalence of various GI disorders and rising consumption of opioids.

Major players operating in the global opioid-induced side effects treatment market are Shionogi & Co Ltd., AstraZeneca plc, Merck & Co Inc, Mallinckrodt Pharmaceuticals, Purdue Pharma L.P., Grünenthal, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals PLC, Sanofi, Pfizer, Inc., and AbbVie Inc.